Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design

J Virol. 2008 Aug;82(15):7700-10. doi: 10.1128/JVI.00605-08. Epub 2008 May 28.

Abstract

The death of CD4(+) CCR5(+) T cells is a hallmark of human immunodeficiency virus (HIV) infection. We studied the plasma levels of cell death mediators and products--tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), Fas ligand, TNF receptor type 2 (TNFR-2), and plasma microparticles--during the earliest stages of infection following HIV type 1 (HIV-1) transmission in plasma samples from U.S. plasma donors. Significant plasma TRAIL level elevations occurred a mean of 7.2 days before the peak of plasma viral load (VL), while TNFR-2, Fas ligand, and microparticle level elevations occurred concurrently with maximum VL. Microparticles had been previously shown to mediate immunosuppressive effects on T cells and macrophages. We found that T-cell apoptotic microparticles also potently suppressed in vitro immunoglobulin G (IgG) and IgA antibody production by memory B cells. Thus, release of TRAIL during the onset of plasma viremia (i.e., the eclipse phase) in HIV-1 transmission may initiate or amplify early HIV-1-induced cell death. The window of opportunity for a HIV-1 vaccine is from the time of HIV-1 transmission until establishment of the latently infected CD4(+) T cells. Release of products of cell death and subsequent immunosuppression following HIV-1 transmission could potentially narrow the window of opportunity during which a vaccine is able to extinguish HIV-1 infection and could place severe constraints on the amount of time available for the immune system to respond to the transmitted virus.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Antibodies, Viral / biosynthesis
  • B-Lymphocytes / immunology
  • Child
  • Child, Preschool
  • Fas Ligand Protein / blood*
  • HIV Infections / immunology*
  • HIV Infections / virology*
  • HIV-1 / physiology*
  • Humans
  • Immune Tolerance*
  • Receptors, Tumor Necrosis Factor, Type II / blood*
  • TNF-Related Apoptosis-Inducing Ligand / blood*
  • Time Factors
  • United States
  • Viral Load

Substances

  • Antibodies, Viral
  • Fas Ligand Protein
  • Receptors, Tumor Necrosis Factor, Type II
  • TNF-Related Apoptosis-Inducing Ligand
  • TNFSF10 protein, human